NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS), a clinical biopharmaceutical firm focused on developing oral, non-statin therapies for cardiovascular disease (CVD), has announced its participation in the Stifel 2025 Virtual Cardiometabolic Forum. This event will take place on September 30, 2025, at 11:00 a.m. ET, featuring key company figures including John Kastelein, Chief Scientific Officer, and Matthew Philippe, Executive Vice President of Investor Relations. The fireside chat will address NewAmsterdam’s innovative approaches in tackling elevated low-density lipoprotein cholesterol (LDL-C) levels among patients at risk of CVD who find existing treatments ineffective or burdensome.

NewAmsterdam Pharma specializes in identifying unmet medical needs within the metabolic disease landscape, striving to deliver effective and patient-friendly LDL-lowering therapies. Central to their research is obicetrapib, an oral CETP inhibitor that is being evaluated in multiple Phase 3 clinical trials. This low-dose, once-daily medication can be utilized alone or combined with ezetimibe to enhance cholesterol management, especially for patients who are unable to achieve desired LDL-C levels through conventional statin therapies.

The upcoming forum offers a platform to discuss the significance of NewAmsterdam's developments in cardiometabolic health and their commitment to patient care. The live webcast will be accessible via the investor relations section of NewAmsterdam's website, ensuring stakeholders can follow the discourse and review archived discussions post-event.

For more information or inquiries, Matthew Philippe can be contacted directly, or representatives from media and investor relations can be reached as detailed in the company’s announcement. This presentation underscores NewAmsterdam's mission to innovate within a critical area of healthcare, aligning with current trends toward personalized and effective treatment solutions.

NewAmsterdam Pharma (Nasdaq: NAMS) is positioned at a pivotal moment as it prepares to present at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025. As a late-stage biopharmaceutical company, NewAmsterdam aims to address the unmet needs for effective LDL-lowering therapies in patients at risk of cardiovascular disease (CVD). The focus on obicetrapib, an oral CETP inhibitor, is particularly noteworthy considering its potential to offer a safe and well-tolerated alternative for patients who have experienced inadequate responses or adverse reactions to existing treatments.

Investors should closely monitor the outcomes of the ongoing Phase 3 trials of obicetrapib, as successful results could catalyze a significant upward movement in NAMS stock. The company’s strategy to combine obicetrapib with ezetimibe for a fixed-dose regimen might broaden its appeal, especially among healthcare providers seeking to enhance treatment efficacy in managing elevated LDL-C levels.

Participating in a well-regarded forum like Stifel not only enhances visibility but also allows management to articulate its value proposition to a wider audience, potentially attracting interest from institutional investors. This could lead to increased analyst coverage and a favorable shift in market sentiment.

Furthermore, stakeholders should assess NewAmsterdam's financial health, including its burn rate and funding pathways, as the clinical development stage can strain cash reserves. The efficacy of its therapies and the outcomes of upcoming trials will be critical in shaping future capital raises or strategic partnerships.

In summary, while the market may still view NewAmsterdam as a speculative investment, the company’s innovative approach and potential to address a critical gap in cardiovascular therapies merit close watching. A successful presentation at the Stifel Forum could serve as a key inflection point for investor confidence and stock performance.